Actively Recruiting
Phase 1 Study to Assess Safety and Effects of VV169 T-cell Therapy for Relapsed or Refractory Multiple Myeloma
Led by Vyriad, Inc. · Updated on 2026-09-21
40
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of an in vivo BCMA-CAR T cell therapy called VV169 for adults with relapsed or refractory multiple myeloma who have previously received treatment and either did not respond or have no other approved therapies available. This Phase 1 trial includes a dose escalation phase to find the optimal dose and a dose expansion phase to further study the treatment. The study is designed to assess safety, pharmacodynamics, and preliminary efficacy. Participants will receive VV169, a T-cell targeted lentiviral vector, through an infusion. The trial includes two phases the dose escalation phase for initial dose finding without prior T-cell engager or BCMA antibody-drug conjugate therapies, and the dose expansion phase where participants may have had these treatments more than 6 months prior or CAR-T therapy more than 9 months prior. Patients who have had stem cell transplants must meet specific recovery criteria before joining. Throughout the study, participants will be monitored for safety and tolerability for up to two years or until disease progression or the start of a new treatment. Researchers will evaluate the maximum tolerated dose, recommended phase 2 dose, and anti-tumor activity of the treatment. Participants will undergo assessments including disease measurement by RECIST criteria, performance status evaluation, and monitoring for side effects and treatment response during scheduled visits.
CONDITIONS
Brief Title
A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here